Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synmosa BiopharmaROCO:4114 -0.84%84 Return-on-Tangible-Equity is 11.64% as of Jun. 2026, which is 8% above its 10-year median of 10.79. GuruFocus rates ROCO:4114 with a GF Score™ of 84/100 and a GF Value™ of NT$33.92 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 899 Drug Manufacturers companies, Synmosa Biopharma ranks better than 57.51% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Synmosa Biopharma's annualized net income for the quarter that ended in Jun. 2026 was NT$954 Mil. Synmosa Biopharma's average shareholder tangible equity for the quarter that ended in Jun. 2026 was NT$8,200 Mil. Therefore, Synmosa Biopharma's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 11.64%.
The historical rank and industry rank for Synmosa Biopharma's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4114'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.17 Med: 10.79 Max: 18.62
Current: 10.12
During the past 13 years, Synmosa Biopharma's highest Return-on-Tangible-Equity was 18.62%. The lowest was 0.17%. And the median was 10.79%.
ROCO:4114's Return-on-Tangible-Equity is ranked better than 57.51% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs ROCO:4114: 10.12
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Synmosa Biopharma Return-on-Tangible-Equity Related Terms
Synmosa Biopharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Synmosa Biopharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4114 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synmosa Biopharma Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Synmosa Biopharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.64% mean?
Synmosa Biopharma (ROCO:4114) has a Return-on-Tangible-Equity of 11.64% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synmosa Biopharma and its competitors. This is near median its historical median of 10.79. Over the past decade, Synmosa Biopharma's Return-on-Tangible-Equity has ranged from 0.17 to 18.62. According to the industry distribution chart, Synmosa Biopharma ranks #382 out of 899 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Synmosa Biopharma's Return-on-Tangible-Equity too high?
Synmosa Biopharma's current Return-on-Tangible-Equity of 11.64% is near median its 10-year median of 10.79. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 18.62. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.50. Synmosa Biopharma's value of 11.64% is 55.2% above this industry median. Based on the distribution chart, Synmosa Biopharma ranks #382 out of 899 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Synmosa Biopharma has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Synmosa Biopharma ranks #382 out of 899 companies for Return-on-Tangible-Equity. This puts Synmosa Biopharma in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.50. Synmosa Biopharma's value of 11.64% is 55.2% above this benchmark. Historically, Synmosa Biopharma's own Return-on-Tangible-Equity has ranged from 0.17 to 18.62 over the past decade. While the company's 10-year median is 10.79 vs. the industry median of 7.50, Synmosa Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.50, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synmosa Biopharma's current Return-on-Tangible-Equity of 11.64% is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synmosa Biopharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synmosa Biopharma's current Return-on-Tangible-Equity is 11.64%, which is near median its own 10-year median of 10.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.92, compared to a current price of NT$29.50 — trading 13% below its estimated fair value. The current Return-on-Tangible-Equity is 11.64%, which is near median its 10-year median of 10.79 and 55.2% above the Drug Manufacturers industry median of 7.50. Synmosa Biopharma's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Return-on-Tangible-Equity is 11.64% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?
Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued.
The current stock price of NT$29.50 is trading 13% below its estimated GF Value™ of NT$33.92.
GuruFocus considers Synmosa Biopharma to be Modestly Undervalued.
Key valuation signals for ROCO:4114:
Return-on-Tangible-Equity: 11.64% (near median its 10-year median of 10.79)
GF Value™: NT$33.92 vs. price of NT$29.50 (13% below fair value)
Industry Position: 55.2% above the Drug Manufacturers median (#382 of 899)
No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
84GF Score
Get the complete analysis for ROCO:4114
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4114 has been successfully added to your 
